Contact | Newsletter | Créer votre compte
(Mise à jour 17:45) Epidémie de choléra dans le nord de la Zambie Neuf Palestiniens meurent de grippe H1N1 en Cisjordanie Pakistan: un sirop contre la toux toxique tue 24 personnes Greffe simultanée de cinq organes: mise au point de l'Académie de chirurgie Un meilleur usage du médicament économiserait 500 milliards de dollars Aluminium dans les vaccins: nouvel apppel aux autorités sanitaires Les secrets dévoilés de l'intestin irritable OGM: Séralini accuse l'autorité sanitaire européenne de faute professionnelle Cholestérol: rappel de génériques de Lipitor aux Etats-Unis Le virus de la variole détecté dans un corps gelé en Sibérie Coronavirus: quatre nouveaux cas d'infection, selon l'OMS Attention aux collyres pour les tout-petits Les hépatites virales mal combattues malgré un million de victimes par an Méningite B : un premier vaccin autorisé en Europe Sida: l'ONU donne des raisons d'espérer Surconsommation d'antibiotiques: mieux encadrer les prescriptions Soudan: vaste campagne de vaccination contre la fièvre jaune au Darfour France - Une partie du monde médical en grève Le Brésil va tester un moustique vacciné contre la dengue La pneumonie, principale cause de mortalité infantile selon l'Unicef
  Home > Actualités médicales > Medical news
 
  First bioabsorbable stent approved in Europe
Abbott Park, IL - The world's first market approved, bioabsorbable stent will soon be available in Europe, with Abbott announcing today that it has received CE Mark approval for the Absorb everolimus-eluting bioresorbable vascular scaffold (BVS) stent. The stent utilizes a poly-L-lactide polymer and is approved for the treatment of coronary artery disease. ... [suite] 0Commentaire(s)
Par : Moderateur : Asirem Le : 2011-01-10 à: 20:59:16

  Pharmacological drugs under investigation show effect on tumor-initiating cells
Scientists from the Vall d’Hebron Institute of Oncology (VHIO) in Barcelona have discovered markers that identify the cells within the tumor that are responsible for the initiation and recurrence of tumors. They have also shown that drugs under clinical development can eliminate these cells, and therefore minimize recurrence and potential resistance of the tumors to conventional chemotherapy in a study published in Cancer Cell. ... [suite] 0Commentaire(s)
Par : Administrateur : admin_actumed Le : 2010-12-30 à: 10:25:36

  Which comes first: Exercise-induced asthma or obesity?
Obese people are more likely to report exercise as a trigger for asthma. Of 673 people evaluated in a new study whose results are published in the journal The Physician and Sportsmedicine, 71 percent of participants reported exercise-induced asthma (ETA). ... [suite] 0Commentaire(s)
Par : Administrateur : admin_actumed Le : 2010-12-28 à: 18:35:23

  ‘Food of the gods’ genome sequence could make finest chocolate better
The production of high quality chocolate, and the farmers who grow it, will benefit from the recent sequencing and assembly of the chocolate tree genome, according to an international team led by Claire Lanaud of CIRAD, France, with Mark Guiltinan of Penn State, and including scientists from 18 other institutions. The team sequenced the DNA of a variety of Theobroma cacao, considered to produce the world’s finest chocolate. The Maya domesticated this variety of Theobroma cacao, Criollo, about 3, ... [suite] 0Commentaire(s)
Par : Administrateur : admin_actumed Le : 2010-12-28 à: 18:33:42

  Seek Early Diagnosis And Treatment For Arthritis, Rheumatologists Urge
In people who develop symptoms of inflammatory arthritis, early diagnosis and treatment can have a significant impact on the course of disease-in some cases even preventing deformity and loss of function from rheumatoid arthritis (RA), according to an article in the December issue of JCR: Journal of Clinical Rheumatology. ... [suite] 0Commentaire(s)
Par : Administrateur : admin_actumed Le : 2010-12-14 à: 10:02:50

  Anti-Obesity Drug Contrave™ Gains FDA Advisory Approval
PharmaDirections congratulates Orexigen Therapeutics on achieving FDA Advisory Board approval for their anti-obesity drug Contrave™. PharmaDirections is proud to have been Orexigen's pharmaceutical development partner and to have developed and produced the first Contrave™ product to undergo full clinical development. ... [suite] 0Commentaire(s)
Par : Administrateur : admin_actumed Le : 2010-12-14 à: 10:00:21

  Audiology centre inaugurated in Algiers
ALGIERS- A National Audiology Centre for hearing-impaired people has been inaugurated Thursday in Algiers by Minister of Labour, Employment and Social Security Tayeb Louh. ... [suite] 0Commentaire(s)
Par : Administrateur : admin_actumed Le : 2010-12-06 à: 19:44:01

  Signing of three ministerial decisions about early screening and treatment availability
ALGIERS- Minister of Health, Population and Hospital Reform Djamal Ould Abbas announced Wednesday here the signing of three ministerial decisions on early screening, availability of treatment and psychological and social assistance to people affected by AIDS. ... [suite] 0Commentaire(s)
Par : Administrateur : admin_actumed Le : 2010-12-06 à: 19:43:11

  Gene Therapy Success in an Immune Disorder
A pediatric immunologist at The Children's Hospital of Philadelphia collaborated with European gene therapy researchers who achieved marked clinical improvements in two young children with Wiskott-Aldrich syndrome, a very rare but often severe immunodeficiency disorder. ... [suite] 0Commentaire(s)
Par : Moderateur : Asirem Le : 2010-12-01 à: 20:48:59

  Researchers Find Sporadic Breast Cancers Start With Ineffective DNA Repair Systems
Breast cancers that arise sporadically, rather than through inheritance of certain genes, likely start with defects of DNA repair mechanisms that allow environmentally triggered mutations to accumulate, according to researchers at the University of Pittsburgh School of Medicine, ... [suite] 0Commentaire(s)
Par : Moderateur : Asirem Le : 2010-12-01 à: 20:44:35

Archives : Début ...2 3 4 5 6 7 8 9 10

Actuellement sur la page : 7

Partenaires
&
Amis d'Actumed

Actualités médicales Formation médicale Autres rubriques
© 2009-2012 / ACTUMED Tous droits réservés